USPTO Examiner FRAZIER BARBARA S - Art Unit 1611

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18414767ETHYL {[N'-(3-CHLOROPHENYL)-N-(2,4-DICHLOROBENZOYL) CARBAMIMIDOYL]SULFANYL}ACETATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024August 2024Allow710YesNo
18414749ETHYL {[N'-(3-CHLOROPHENYL)-N-(2,4-DICHLOROBENZOYL) CARBAMIMIDOYL]SULFANYL}ACETATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024September 2024Allow810YesNo
18404706THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDEJanuary 2024July 2024Allow710YesNo
18483283ETHYL {[N'-(3-CHLOROPHENYL)-N-(2,4-DICHLOROBENZOYL) CARBAMIMIDOYL]SULFANYL}ACETATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)October 2023April 2024Allow611NoNo
18219446COMPOSITIONS OF ASPIRIN AND KETAMINEJuly 2023August 2024Abandon1311NoNo
18218178Micronutrient composition to prevent and reverse protein glycation during oxidative stress in humanJuly 2023February 2025Abandon2031YesNo
18118479MODIFIED RELEASE FORMULATIONS AND USES THEREOFMarch 2023August 2024Allow1710YesNo
18100616MEDICAMENT DELIVERY FORMULATIONS, DEVICES AND METHODSJanuary 2023February 2025Abandon2531NoNo
17936562COMPOSITIONS FOR THE IMPROVED TREATMENT OF ACNE AND RELATED DISORDERSSeptember 2022May 2024Abandon2010NoNo
17902440COMPOSITIONS COMPRISING KAKADU PLUM EXTRACT OR ACAI BERRY EXTRACTSeptember 2022August 2024Allow2411YesNo
17878259PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASEAugust 2022September 2023Abandon1411NoNo
17845012MESOSTIGMATA MITE CONTROL AGENTJune 2022July 2024Allow2511YesNo
17741707COSMETIC MASK FOR APPLICATION TO THE SKIN, AND METHOD FOR APPLYING SAMEMay 2022July 2024Abandon2611NoNo
17721864COMPOSITE MATERIAL INCLUDING A THERMOPLASTIC POLYMER, A PEST FOOD MATERIAL, AND A PESTICIDEApril 2022October 2024Abandon3010NoNo
17690611COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOFMarch 2022May 2023Allow1421YesNo
17667746PHARMACEUTICAL FORMULATIONFebruary 2022November 2024Allow3320NoNo
17646805STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATIONJanuary 2022June 2024Allow2912YesNo
17545628NON-ABLATIVE MULTI-LAYER COATINGS THAT PREVENT WATER-DERIVED DAMAGE, CORROSION, AND DETERIORATION FROM BIOLOGICAL CHEMICAL PROCESSESDecember 2021January 2023Allow1411YesNo
17608905SYNERGISTIC BIOACTIVE COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERSNovember 2021May 2024Allow3050YesNo
17513192METHODS OF PROTECTING SEEDS FROM OXIDANTS AND MICROORGANISMSOctober 2021December 2023Allow2510YesNo
17500332PHARMACEUTICAL COMPOSITIONS COMPRISING CHROMIUM AND CARBOHYDRATE BLOCKERSOctober 2021December 2024Abandon3821NoNo
17499498PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USEOctober 2021April 2024Allow3020NoNo
17497117Natural Component Tick RepellentOctober 2021September 2024Abandon3511NoNo
17490616MODIFIED RELEASE FORMULATIONS AND USES THEREOFSeptember 2021December 2022Allow1411YesNo
17478268COMPOSITIONS AND METHODS FOR TREATING MICROBIOTA-RELATED PSYCHOTROPIC CONDITIONS AND DISEASESSeptember 2021December 2024Abandon3921NoNo
17465972PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASESeptember 2021April 2022Allow811YesNo
17349916SOLID DOSAGE FORMS OF PALBOCICLIBJune 2021October 2023Abandon2810NoNo
17348471PHARMACEUTICAL COMPOSITION AND USEJune 2021July 2024Allow3721YesNo
17413358COMPOUNDS, COMPOSITIONS CONTAINING SAME, AND USE THEREOF FOR PROMOTING HAIR GROWTHJune 2021February 2024Allow3311YesNo
17308007COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOFMay 2021March 2023Allow2231YesNo
17237361METHODS FOR TREATING AND PREVENTING NOCICEPTIVE PAINApril 2021September 2023Abandon2901NoNo
17229200HYALURONATE COMPOSITIONS AND SOFT TISSUE FILLERSApril 2021September 2023Allow2911NoNo
17227370HEALTH-CARE PRODUCT COMPOSITION FOR ENRICHING ASTHENIC DISEASE, PREPARATION METHOD THEREFOR AND USE THEREOFApril 2021January 2025Abandon4511NoNo
17215988Low pH Skin Care Composition and Methods of Using the SameMarch 2021October 2023Allow3011YesNo
17300136Novel formulation of meloxicamMarch 2021October 2023Abandon3110NoNo
17275849COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONSMarch 2021February 2024Allow3511NoNo
17198283Constituent combination for treating stressMarch 2021January 2024Abandon3411NoNo
17198366PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASEMarch 2021June 2021Allow311YesNo
17191582METHODS AND COMPOSITIONS FOR IMPROVING THE PROPERTIES AND PRODUCTIVITY OF PLANTSMarch 2021January 2025Abandon4631YesNo
17183110ANTIVIRAL VINYL-CHLORIDE RESIN COMPOSITION, ANTIVIRAL SHEET OF VINYL-CHLORIDE RESIN, PROCESS FOR PRODUCING THE SAME, INTERIOR DECORATIVE SHEET, PROCESS FOR PRODUCING INTERIOR DECORATIVE SHEET, INTERIOR DECORATIVE SHEET OF POLY(VINYL CHLORIDE) RESIN, ANTIVIRAL WALLPAPER, AND PROCESS FOR PRODUCING ANTIVIRAL WALLPAPERFebruary 2021January 2024Allow3411YesNo
17156809PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTINJanuary 2021April 2024Abandon3921NoNo
17149105COMPOSITIONS COMPRISING KAKADU PLUM EXTRACT OR ACAI BERRY EXTRACTJanuary 2021April 2025Abandon5140YesNo
17142600SPATIAL INSECT REPELLENT COMPOSITIONSJanuary 2021August 2023Allow3121YesNo
17136162COMPOSITION FOR INCREASING PRODUCTIVITY IN PLANTSDecember 2020October 2023Allow3421NoNo
17126878THERMOPLASTIC MATERIALS HAVING BENEFICIAL PROPERTIES AND PROCESSES FOR PROVIDING THE SAMEDecember 2020July 2023Abandon3101NoNo
17059124METHODS FOR PROMOTING HAIR GROWTHNovember 2020May 2024Abandon4110NoNo
17100652TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATIONNovember 2020June 2023Allow3111YesNo
16952845METHODS FOR PREVENTION AND TREATMENT OF UROGENITAL ATROPHY OF MENOPAUSE BY CONTACT VASODILATORSNovember 2020July 2023Abandon3251NoNo
17057058COMPOSITION OF MULTIVITAMIN FOR STIMULATING GASTROINTESTINAL SYSTEM MOTILITY AND PREPARATION METHOD THEREFORNovember 2020July 2024Allow4421YesNo
16949792INSECT BAIT COMPOSITION AND METHODS OF USE OF THE SAMENovember 2020July 2024Abandon4421NoNo
17093715METHOD FOR PREVENTING OR REDUCING GROWTH OF A MICROORGANISM ON A SURFACENovember 2020April 2023Allow2911YesNo
17090837COSMETIC COMPOSITION AND PREPARATION METHODNovember 2020September 2023Abandon3511NoNo
17066172ADJUVANT COMPOSITION CONTAINING ALUMINUM AND VACCINE COMPOSITION CONTAINING THE SAMEOctober 2020June 2023Abandon3211NoNo
17061321COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOFOctober 2020April 2021Allow711YesNo
17038920APPLICATION OF METHYLMALONIC ACID IN THE PREPARATION OF NEMATODE INSECTICIDESSeptember 2020March 2023Allow3010YesNo
17025156COMPOSITIONS FOR THE IMPROVED TREATMENT OF ACNE AND RELATED DISORDERSSeptember 2020November 2022Abandon2610NoNo
16981893PESTICIDESeptember 2020November 2023Abandon3821NoNo
17021124PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASESeptember 2020January 2021Allow411YesNo
16975642HERBICIDALLY ACTIVE BICYCLIC BENZAMIDESAugust 2020January 2025Allow5311YesNo
16963563AGRICULTURAL AND HORTICULTURAL FUNGICIDE COMPOSITIONJuly 2020October 2022Allow2610NoNo
16963021METHOD AND COMPOSITION FOR COLOURING AN EYEBROW COMPRISING AN ORGANIC ACIDJuly 2020February 2023Allow3111NoNo
16922411METHOD FOR SCAVENGING HYDROGEN PEROXIDE AND REGULATING GASTROINTESTINAL FUNCTION BY USING DRINKING WATER COMPRISING SILICON DIOXIDEJuly 2020November 2022Abandon2911NoNo
16918687METHIONINE METABOLIC PATHWAY INHIBITORSJuly 2020December 2022Allow3011NoNo
16955745DITHIAZOCANE COMPOUNDS FOR THE COSMETIC USE THEREOFJune 2020September 2022Abandon2701NoNo
16954917SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCESJune 2020December 2022Abandon3001NoNo
16772537PLANT GROWTH REGULATIONJune 2020July 2023Allow3721YesNo
16892641MODIFIED RELEASE FORMULATIONS AND USES THEREOFJune 2020June 2021Allow1320YesNo
16891491Low pH Skin Care Composition and Methods of Using the SameJune 2020February 2021Allow811YesNo
16886239COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOFMay 2020April 2021Allow1111YesNo
16767398HERBICIDAL COMBINATIONSMay 2020January 2025Abandon5561YesNo
16765678Fungicidal CompositionsMay 2020October 2022Allow2810YesNo
16764461PROCESS FOR PERMANENT WAVING KERATIN FIBERSMay 2020August 2024Abandon5121NoYes
15931910APIXABAN FORMULATIONSMay 2020June 2021Abandon1301NoNo
16871831ANTIMICROBIAL PARTICLES AND SANITIZATION METHODSMay 2020December 2024Abandon5531NoNo
16866136PHARMACEUTICAL CAPSULE CONTAINING AT LEAST TWO TABLETSMay 2020September 2023Abandon4121NoNo
16860188DISINFECTION FORMULATION AND DISINFECTION METHODApril 2020February 2023Allow3421YesNo
16759310All-in-one lyophilized multivitamin emulsion for parenteral applicationApril 2020July 2023Allow3941YesNo
16852603EMULSION AND EMULSION PRECONCENTRATE COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND USES THEREOFApril 2020September 2022Abandon2911NoNo
16853164COMPOSITE MATERIAL INCLUDING A THERMOPLASTIC POLYMER, A PEST FOOD MATERIAL, AND A PESTICIDEApril 2020February 2022Allow2220YesNo
16755396BENZIMIDAZOLE COMPOUNDS AS AGRICULTURAL CHEMICALSApril 2020October 2022Abandon3001NoNo
16754910PESTICIDE COMPOSITION CONTAINING THIDIAZURON AND POLYGLUTAMIC ACIDApril 2020October 2022Allow3010NoNo
16754856METHOD OF PREPARATION OF FLORASULAMApril 2020May 2024Allow4930YesNo
16841861HYALURONATE COMPOSITIONS AND SOFT TISSUE FILLERSApril 2020March 2021Allow1121YesNo
16649627Pyrimidin-4-Carbamate or Urea Derivatives As HerbicidesMarch 2020December 2023Abandon4551NoNo
16644518COSMETIC MASK FOR APPLICATION TO THE SKIN, AND METHOD FOR APPLYING SAMEMarch 2020June 2022Abandon2711NoNo
16810207Hair Care Compositions Comprising Malodor Reduction CompositionsMarch 2020September 2021Allow1810YesNo
16810222Hair Care Compositions Comprising Malodor Reduction CompositionsMarch 2020September 2021Allow1810YesNo
16809714PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASEMarch 2020September 2020Allow611YesNo
16810233Tamper-resistant dosage form containing ethylene-vinyl acetate polymerMarch 2020January 2022Allow2211YesNo
16638450PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVESFebruary 2020February 2022Allow2421NoYes
16777866TRIMEGESTONE (TMG) FOR TREATMENT OF PRETERM BIRTHJanuary 2020December 2021Abandon2311NoNo
16774709Antimicrobial Compositions with Effervescent AgentsJanuary 2020April 2023Abandon3931NoNo
16751811PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USEJanuary 2020July 2021Allow1820NoNo
16748873COMPOSITION BASED ON TANNINS AND SAPONINS FOR CONTROLLING PLANT PARASITIC NEMATODESJanuary 2020September 2022Abandon3211NoNo
16727610COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTERDecember 2019March 2022Abandon2711NoNo
16725316COMPOSITION FOR TREATING WOUNDS, DERMATITIS, INFLAMMATION, AND IRRITATIONDecember 2019July 2023Allow4341YesNo
16625281ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ORGANIC ACID COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAMEDecember 2019April 2023Abandon4041YesNo
16723230COSMETIC COMPOSITION AND ITS USE, DERMOCOSMETIC FORMULATIONDecember 2019September 2022Allow3211NoNo
16718293INHIBITION OF EXOCYTOSIS AND THE USES THEREOFDecember 2019December 2022Abandon3621NoNo
16717151Personal Care Composition With Increased Vapor ReleaseDecember 2019August 2021Allow2020NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FRAZIER, BARBARA S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
36
Examiner Affirmed
32
(88.9%)
Examiner Reversed
4
(11.1%)
Reversal Percentile
22.0%
Lower than average

What This Means

With a 11.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
120
Allowed After Appeal Filing
19
(15.8%)
Not Allowed After Appeal Filing
101
(84.2%)
Filing Benefit Percentile
16.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner FRAZIER, BARBARA S - Prosecution Strategy Guide

Executive Summary

Examiner FRAZIER, BARBARA S works in Art Unit 1611 and has examined 799 patent applications in our dataset. With an allowance rate of 45.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner FRAZIER, BARBARA S's allowance rate of 45.3% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by FRAZIER, BARBARA S receive 2.39 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by FRAZIER, BARBARA S is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +12.2% benefit to allowance rate for applications examined by FRAZIER, BARBARA S. This interview benefit is in the 52% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.5% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 24.6% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 48.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 47.8% of appeals filed. This is in the 9% percentile among all examiners. Of these withdrawals, 48.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.3% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 66% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 50% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.